P/E ratio for AstraZeneca (AZN)
P/E ratio as of March 2023 (TTM): 64.8
According to AstraZeneca's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 64.8396. At the end of 2021 the company had a P/E ratio of 402.
P/E ratio history for AstraZeneca from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 402 | 880.4% |
| 2020 | 41.0 | -57.68% |
| 2019 | 96.8 | 116.68% |
| 2018 | 44.7 | 52.59% |
| 2017 | 29.3 | 48.32% |
| 2016 | 19.7 | -35.16% |
| 2015 | 30.4 | -57.6% |
| 2014 | 71.8 | 146.77% |
| 2013 | 29.1 | 207.22% |
| 2012 | 9.47 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 22.4 | -65.38% | 🇺🇸 USA |
 Novartis NVS | 28.3 | -56.35% | 🇨🇭 Switzerland |
 Pfizer PFE | 7.18 | -88.92% | 🇺🇸 USA |
 Abbott Laboratories ABT | 22.9 | -64.64% | 🇺🇸 USA |
 Eli Lilly LLY | 49.9 | -23.11% | 🇺🇸 USA |
 Sanofi SNY | 18.7 | -71.15% | 🇫🇷 France |
 Biogen BIIB | 12.9 | -80.16% | 🇺🇸 USA |
 Merck MRK | 18.7 | -71.22% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 25.0 | -61.40% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 4.43 | -93.17% | 🇬🇧 UK |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.